Use of win time for ordered composite endpoints in clinical trials
Statistics in Medicine · 2024-05-10 · 43 (10) · 1920-1932
DOI: 10.1002/sim.10045 ↗At a glance
Journal article in Statistics in Medicine, published online on 2024-02-28. Written by James F Troendle and 6 co-authors. Institution: Office of Biostatistics Research, Division of Intramural Research of the National Heart, Lung, and Blood Institute, NIH/DHHS, Bethesda, Maryland, USA. Major MEDLINE topics: Heart Failure. Cited 8 times so far (Crossref); 14 references. The full text is freely available (open access, CC BY 4.0). Funded by: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (original language)
Consider the choice of outcome for overall treatment benefit in a clinical trial which measures the first time to each of several clinical events. We describe several new variants of the win ratio that incorporate the time spent in each clinical state over the common follow‐up, where clinical state means the worst clinical event that has occurred by that time. One version allows restriction so that death during follow‐up is most important, while time spent in other clinical states is still accounted for. Three other variants are described; one is based on the average pairwise win time, one creates a continuous outcome for each participant based on expected win times against a reference distribution and another that uses the estimated distributions of clinical state to compare the treatment arms. Finally, a combination testing approach is described to give robust power for detecting treatment benefit across a broad range of alternatives. These new methods are designed to be closer to the overall treatment benefit/harm from a patient's perspective, compared to the ordinary win ratio. The new methods are compared to the composite event approach and the ordinary win ratio. Simulations show that when overall treatment benefit on death is substantial, the variants based on either the participants' expected win times (EWTs) against a reference distribution or estimated clinical state distributions have substantially higher power than either the pairwise comparison or composite event methods. The methods are illustrated by re‐analysis of the trial heart failure: a controlled trial investigating outcomes of exercise training.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Office of Biostatistics Research, Division of Intramural Research of the National Heart, Lung, and Blood Institute, NIH/DHHS, Bethesda, Maryland, USA.
- Inova Heart and Vascular Institute, Fairfax, Virginia, USA.
ORCID profiles: James F Troendle, Song Yang, Dong-Yun Kim
Funding
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Cite
APA
Troendle, J. F., Leifer, E. S., Yang, S., Jeffries, N., Kim, D. Y., Joo, J., & O'Connor, C. M. (2024). Use of win time for ordered composite endpoints in clinical trials. Statistics in Medicine, 43(10), 1920-1932. https://doi.org/10.1002/sim.10045
Vancouver
Troendle JF, Leifer ES, Yang S, Jeffries N, Kim DY, Joo J, et al. Use of win time for ordered composite endpoints in clinical trials. Statistics in Medicine. 2024;43(10):1920-1932. doi:10.1002/sim.10045
BibTeX
@article{Troendle2024,
author = {Troendle, James F and Leifer, Eric S and Yang, Song and Jeffries, Neal and Kim, Dong-Yun and Joo, Jungnam and O'Connor, Christopher M},
title = {Use of win time for ordered composite endpoints in clinical trials},
journal = {Statistics in Medicine},
year = {2024},
volume = {43},
number = {10},
pages = {1920--1932},
doi = {10.1002/sim.10045}
}
EUVIMED